CTIS2023-506393-12-00招募中1 期
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer
Johnson And Johnson Enterprise Innovation Inc.0 个研究点目标入组 67 人开始时间: 2023年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerCarcinoma, Non-small-Cell LungNCT06116786Johnson & Johnson Enterprise Innovation Inc.67
未知
2 期
Phase-II study of AJA777 in patients with functional dyspepsiaFunctional dyspepsia (recruited according to the ROME III criteria)JPRN-jRCT2080221822Ajinomoto Pharmaceuticals Co., Ltd.
未知
2 期
Phase-IIa study of AJA777 in patients with functional dyspepsiaFunctional dyspepsia (recruited according to the ROME III criteria)JPRN-jRCT2080221048Ajinomoto Pharmaceuticals Co., Ltd.
进行中（未招募）
1 期
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerProstatic NeoplasmsAdenocarcinomaNCT04644770Janssen Research & Development, LLC144
进行中（未招募）
1 期
Alisertib in relapsed or refractory urothelial cancerAdvanced urotelial cancer of the bladder, urethra, or the upper urinary tract who are resistant to platinum based therapyMedDRA version: 16.1Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000557-36-ITFondazione IRCCS Istituto Nazionale dei tumori130